Nodal peripheral T-cell lymphoma: a prognostic index developed by the T-cell project

To characterize real-world treatment patterns and outcomes in nodal peripheral T-cell lymphoma (PTCL) and to develop and externally validate a contemporary clinical prognostic model, we analyzed patients prospectively registered in the International T-Cell Project 2 (TCP2). Between January 2018 and January 2026, 1,465 patients with PTCL were registered; 959 with nodal PTCL by the 2016 WHO classification (PTCL not otherwise specified (PTCL-NOS), systemic anaplastic large-cell lymphoma (ALCL; ALK-positive or ALK-negative), and T-follicular helper lymphoma (TFHL)) were analyzed. The primary endpoint was 2-year progression-free survival (PFS); the model was externally validated in the TCP1 cohort (n = 1,016). The cohort comprised 396 PTCL-NOS (41%), 263 TFHL (27%), 211 ALK-negative ALCL (22%), and 89 ALK-positive ALCL (9%). First-line therapy was CHOEP in 340 (37%), CHOP in 260 (29%), and brentuximab vedotin-CHP in 139 (15%); 156 underwent consolidative stem cell transplantation. After a median follow-up of 25.3 months, 2-year PFS and overall survival were 35.3% and 54.3%, respectively. In multivariate analysis, diagnosis other than ALCL, age ≥65 years, ECOG performance status ≥2, thrombocytopenia, extranodal involvement, and elevated LDH were independently associated with inferior PFS. A six-variable score using these factors stratified patients into 3 risk groups - low (score 0-1), intermediate (2-3), and high (4-6) with 2-year PFS, 65%, 33%, and 16% respectively (P < .001) and was confirmed in the TCP1 validation cohort. Outcomes for nodal PTCL remain poor with current therapy; the externally validated TCP score offers a contemporary, complementary tool for risk stratification and identification of patients at high risk of treatment failure. ClinicalTrials.gov NCT03964480, NCT01142674.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-18
DOI
https://doi.org/10.1182/bloodadvances.2026021721
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nodal peripheral T-cell lymphoma: a prognostic index developed by the T-cell project

Yasodha Natkunam, CARLOS SÉRGIO CHIATTONE, Eliza Anne Hawkes, Raimundo Gazitúa et al.
2 links
Blood Advances
Lymphoma Diagnosis and Treatment
article

Nodal peripheral T-cell lymphoma: a prognostic index developed by the T-cell project

Yasodha Natkunam, CARLOS SÉRGIO CHIATTONE, Eliza Anne Hawkes, Raimundo Gazitúa, Danielle Leão Cordeiro de Farias, Eliza Chung, Thais Rodrigues da Cunha Fischer, Henry Miles Prince, Luana Conte, Massimo Federico, Fernando Warley, Giorgio De Nunzio, Nazar Shokun, Iryna Kryachok, Camila Peña, Francine M. Foss, K. Filonenko, Lorena Fiad, Iryna Tytorenko, Carolina Valeria Mahuad, Ranjana H. Advani, Ilias Stagakis, Julie Marie Vose, Silvia Gambara, Ciprian Tomuleasa, Cameron J. Wellard, Tetiana Skrypets, Graciela Alfonso, Stefano Luminari, Neeraj Arora, Won Seog Kim, Sabina Ioana Doinita Iluta
article en

Abstract

To characterize real-world treatment patterns and outcomes in nodal peripheral T-cell lymphoma (PTCL) and to develop and externally validate a contemporary clinical prognostic model, we analyzed patients prospectively registered in the International T-Cell Project 2 (TCP2). Between January 2018 and January 2026, 1,465 patients with PTCL were registered; 959 with nodal PTCL by the 2016 WHO classification (PTCL not otherwise specified (PTCL-NOS), systemic anaplastic large-cell lymphoma (ALCL; ALK-positive or ALK-negative), and T-follicular helper lymphoma (TFHL)) were analyzed. The primary endpoint was 2-year progression-free survival (PFS); the model was externally validated in the TCP1 cohort (n = 1,016). The cohort comprised 396 PTCL-NOS (41%), 263 TFHL (27%), 211 ALK-negative ALCL (22%), and 89 ALK-positive ALCL (9%). First-line therapy was CHOEP in 340 (37%), CHOP in 260 (29%), and brentuximab vedotin-CHP in 139 (15%); 156 underwent consolidative stem cell transplantation. After a median follow-up of 25.3 months, 2-year PFS and overall survival were 35.3% and 54.3%, respectively. In multivariate analysis, diagnosis other than ALCL, age ≥65 years, ECOG performance status ≥2, thrombocytopenia, extranodal involvement, and elevated LDH were independently associated with inferior PFS. A six-variable score using these factors stratified patients into 3 risk groups - low (score 0-1), intermediate (2-3), and high (4-6) with 2-year PFS, 65%, 33%, and 16% respectively (P < .001) and was confirmed in the TCP1 validation cohort. Outcomes for nodal PTCL remain poor with current therapy; the externally validated TCP score offers a contemporary, complementary tool for risk stratification and identification of patients at high risk of treatment failure. ClinicalTrials.gov NCT03964480, NCT01142674.

Blood Advances
University of Modena and Reggio Emilia (IT), University of Salento (IT), The University of Melbourne (AU), Iuliu Hațieganu University of Medicine and Pharmacy (RO), Kantonsspital St. Gallen (CH), Santa Casa Hospital (BR), Peter MacCallum Cancer Centre (AU), Samsung Medical Center (KR), Hospital Italiano de Buenos Aires (AR), AC Camargo Hospital (BR), Yale University (US), Tata Medical Center (IN), Hospital del Salvador (CL), Faculdade de Ciências Médicas da Santa Casa de São Paulo (BR), Beneficência Portuguesa de São Paulo (BR), Hospital Italiano La Plata (AR), National Cancer Institute (UA), Fundación Arturo López Pérez (CL), Hospital Alemán (AR), Hospital Posadas (AR), Universidad Hospital Italiano (AR), Monash University (AU), University of Nebraska Medical Center (US), Sungkyunkwan University (KR), Stanford University (US)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon